top of page

Blog

Clare Koning pic.jpg

Blog Author: Clare Koning

Clare is a freelance healthcare writer and registered nurse with over 20 years of international experience. She specializes in evidence-based health communications and currently leads digital content strategy and development for the T2D Network.

Written by Clare Koning, RN, PhD Clare Koning, RN, PhD is a senior medical writer and healthcare communications consultant with 20+ years of international experience across nursing leadership, clinical operations, and scientific publications. She specializes in translating complex clinical and scientific data into clear, high-impact content for healthcare professionals and patients.

Fatty Liver and Type 2 Diabetes: The Complication Most People Have Never Been Told About

Writer: T2D Network
T2D Network
3 days ago
4 min read

Written by Clare Koning, RN, PhD | 6 min read


Key Highlights

✅ Between roughly 4 and 7 in 10 people with type 2 diabetes have fatty liver disease

✅ In a 2026 study, 10% of those diagnosed with T2D already had clinically significant liver fibrosis and 3% had cirrhosis

✅ US data show serious liver scarring is rising

✅ A simple two-step screening approach can find liver scarring

✅ Fatty liver can improve, and weight loss has been shown to reduce liver fat



Ask most people with type 2 diabetes about their risk of complications and they will mention eyes, kidneys, feet and heart. Very few will mention the liver. Yet fatty liver disease is one of the most common conditions that travels alongside T2D, and it can progress quietly for years.


The condition used to be called non-alcoholic fatty liver disease. It is now called metabolic dysfunction-associated steatotic liver disease, or MASLD, a name that points to its real driver: the same insulin resistance and excess fat storage that sit at the heart of T2D. A 2026 review in EXCLI Journal describes the relationship as a vicious cycle, in which MASLD worsens insulin resistance and glucose metabolism while diabetes accelerates liver disease progression.



How Common Is It?


The numbers depend on who is being studied and how the liver is measured, but they are consistently high.


The same EXCLI review notes that more than 65% of people with T2D have MASLD. In a 2026 multicentre study of outpatients with T2D published in Diabetes, Obesity and Metabolism, MASLD was present in 71.3% of participants and significant liver fibrosis in 21.1%. A 2025 primary care study in the Journal of Internal Medicine found that nearly 60% of the people studied had fatty liver, although only a small fraction showed more advanced damage. Obesity mattered: early liver scarring appeared in 13% of those with obesity compared with 2% of those without.


Even people who are newly diagnosed are not exempt. A 2026 study in the World Journal of Hepatology looked at people diagnosed with T2D less than five years earlier, with no microvascular complications. MASLD affected 41.4%, 10% had clinically significant fibrosis, and 3% had cirrhosis. The authors concluded that liver health screening should be part of routine evaluation from the time of diagnosis, even in people with good glycemic control.


Fatty liver is not a rare add-on to type 2 diabetes. In several 2025 and 2026 studies, it affected the majority of people with T2D.
people

A Mixed Trend: Less Fat, More Scarring


One of the more striking recent findings comes from US national data. A study in the Journal of the Endocrine Society compared 2017 to 2020 with 2021 to 2023 and found that MASLD prevalence fell among adults with diabetes, from 69.4% to 61.4%. That sounds like good news. But over the same period, clinically significant fibrosis in people with diabetes reached 27.4%, and cirrhosis nearly doubled to 10.2%.


In other words, fewer people may have fat in the liver, but among those who do, more are developing the scarring that matters. This is why the question for clinicians and patients is no longer "is there fat in the liver?" but "is there scarring?"



The EXCLI review adds that in biopsy-based studies of people with T2D, pooled prevalence of significant fibrosis was about 41% and advanced fibrosis about 15%, and that fibrosis progressed faster in people with T2D than in people without diabetes in one study of 447 patients with paired biopsies. Biopsy cohorts are selected populations, so those figures are higher than what is seen in routine care, but the direction of the finding is consistent.


Why You May Never Have Been Screened for Fatty Liver


Fatty liver and early fibrosis rarely cause symptoms. Liver enzymes on a routine blood panel can be normal even when scarring is present. And diabetes visits are, understandably, crowded with other priorities.


farming

Current approaches use a staged strategy. First, a blood-test-based score called FIB-4 is calculated. If it suggests risk, a liver stiffness measurement by transient elastography (often called FibroScan) is done. The 2026 Diabetes, Obesity and Metabolism study tested exactly this two-tier approach and concluded that it works well in real-world settings. It also contained an important caution: among people with a normal FIB-4, 16.7% still had a liver stiffness of 8 kPa or higher. FIB-4 is a useful first filter, but a normal result is not a guarantee.


What Can You Do?


The most important step is to ask. At your next diabetes visit, you can ask whether your liver has been assessed, whether a FIB-4 score can be calculated from your existing bloodwork, and whether further testing makes sense for you.


The good news is that this condition responds to the same things that help blood sugar. Fatty liver is not irreversible, and weight loss has been shown to significantly reduce liver fat. A 2026 prospective study in people with T2D is also examining which factors help the liver stay free of steatosis and fibrosis over two years, a reminder that this is an active and hopeful research area. The EXCLI review also covers pharmacologic options that your care team can discuss if your liver risk is high.


For providers, the practical message from these studies is consistent: build liver assessment into the T2D annual review, use FIB-4 first, and follow up with elastography where indicated.


For more on eating and activity strategies, visit the T2D Network's Healthy Eating and Healthy Lifestyle pages. This post is for information only and is not medical advice.



bottom of page